-
The New England Journal of Medicine publishes the results of Roche's oral drug Risdiplam for the treatment of SMA
Time of Update: 2021-03-23
On February 25, 2021, the "New England Journal of Medicine" published the data results of the first part of the FIREFISH study of Risdiplam in children with type 1 SMA, and this article is hereby collated and reported.
-
Roche releases new data from two-year study of risdiplam in the treatment of infants, children and adults with SMA
Time of Update: 2020-07-12
SUNFISH is a two-part, two-part study of SMA children and adult patients (n-231) The first part of the study (n-51) focused on determining the dose, including a wide range of patients, from unable to
-
Roche releases new data from two-year study of risdiplam in the treatment of infants, children and adults with SMA
Time of Update: 2020-06-26
Guide: Rocherisdiplam has obtained positive data on patients who have used both therapies in the treatment, or will further increase risdiplam's advantages and competitiveness in the market , Roche's
-
FDA delays review of Roche's new SMA drug Risdiplam
Time of Update: 2020-05-30
Roche's Gene Tekannounc announced on April 7 that the FDA had extended the approval date for Risdiplam's new drug application for spinal muscular dystrophy (SMA), with the PDUFA date being postponed b
-
Spinal muscular atrophy (SMA) is the first oral drug! Risdiplam, Roche's splicing modifier, has entered the priority review in the United States!
Time of Update: 2019-11-26
November 26, 2019 / biourn / -- Roche recently announced that the U.S Food and Drug Administration (FDA) has accepted risdiplam's new drug application (NDA) and granted priority review The drug is a s